Arrowhead Pharmaceuticals (ARWR) saw its stock surge 5.49% during intraday trading on Wednesday, reflecting strong investor confidence in the company's growth trajectory.
The rally was fueled by Morgan Stanley raising its price target on Arrowhead to $48 from $45, while maintaining an Equal Weight rating. Additionally, TD Cowen reiterated its Buy rating, citing promising developments in the Redemplo launch and strategic advancements in obesity treatments. These analyst actions underscore the market's optimism about Arrowhead's future performance.